You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新華製藥(000756.SZ):格列美脲片、頭孢拉定膠囊參與全國藥品集採中標
格隆匯 01-20 16:53

格隆匯1月20日丨新華製藥(000756.SZ)公佈,2020117日,公司參加了聯合採購辦公室(“聯採辦”)組織的第二批全國藥品集中採購的投標工作公司根據《國家食品藥品監督管理總局關於發佈化學藥品註冊分類改革工作方案的公告》2016 年第51 號〕,按化學藥品新註冊分類批准的仿製藥品格列美脲片(1mg2mg)、頭孢拉定膠囊(0.25g)參加了此次集中採購,2個品種三個規格中標此次集中採購,並且公司根據各省市場潛力進行了省遴選。

就上述中標品種,格列美脲片在此次5中標企業中,中標價格位列第二高位,頭孢拉定膠囊在此次3中標企業中,中標價格最高。

此次中標將有利於公司充分發揮格列美脲原料藥及製劑一體化生產優勢,且公司已經做好充分的生產準備可以確保本標期內(三年)原料藥和製劑市場供應

此次中標將有利於上述產品在通過一致性評價後,快速擴大其國內市場的銷售覆蓋面,提高市場佔有率和品牌影響力,有利於推進公司“大製劑戰略”實施步伐,對公司未來經營業績產生積極的影響。

此次國家組織藥品集中採購和使用工作,由全國各省和新疆生產建設兵團組成採購聯盟,聯盟集中採購產生結果後,即在全國範圍同步實施,在執行上要求確保中選藥品質量、供應、採購使用和及時回款。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account